Search results for "DMI"

showing 10 items of 7539 documents

Diagnosis of Influenza: Only a Problem of Coding?

2013

<b><i>Objective:</i></b> To evaluate the characteristics of hospital discharge diagnoses of influenza measured by using specific International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9 CM) codes. <b><i>Subjects and Methods:</i></b> The study was conducted for the 3 years 2007, 2008 and 2011. The database included (1) administrative and clinical data on Sicilian patients admitted to acute care hospitals and (2) data from the influenza virological surveillance of 10 European countries (FluNet database). All Sicilian patients diagnosed with at least 1 ICD-9 CM code for influenza (487.0, 487.1 and 487.9) were considere…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyeducationSettore MED/42 - Igiene Generale E ApplicataYoung AdultPatient AdmissionInternational Classification of DiseasesInfluenza HumanHospital discharge recordsEpidemiologyInfluenza-like illnessmedicineHospital dischargeHumansPublic Health SurveillanceMedical diagnosisChildhealth care economics and organizationsEpidemiology.AgedInfluenza-like illneOriginal PaperInfluenza-like illnessbusiness.industryInfant Newbornvirus diseasesInfantReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseasePatient DischargeInfluenzaEuropeChild PreschoolInfluenza · Hospital discharge records · Influenza-like illness · EpidemiologyFemaleSeasonsMedical emergencybusinessHospital discharge recordCoding (social sciences)Medical Principles and Practice
researchProduct

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a …

2007

Abstract Background To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carboh…

AdultMalemedicine.medical_specialtyAdolescentMaximum Tolerated DoseOrganoplatinum CompoundsPhases of clinical researchKaplan-Meier EstimateDeoxycytidineRisk AssessmentGastroenterologyDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind MethodProgression-free survivalInfusions IntravenousCapecitabineAgedNeoplasm StagingProbabilityDose-Response Relationship Drugbusiness.industryCAPOX RegimenHematologyMiddle AgedImmunohistochemistrySurvival AnalysisGemcitabineGemcitabineOxaliplatinSurgeryOxaliplatinPancreatic NeoplasmsRegimenTreatment OutcomeOncologyTolerabilityFemaleFluorouracilbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressi…

2003

OBJECTIVE Current clinical knowledge holds that antidepressants have a delayed onset of efficacy. However, the delayed onset hypothesis has been questioned recently by survival analytical approaches. We aimed to test whether early improvement under antidepressant treatment is a clinically useful predictor of later stable response and remission. METHOD We analyzed data from a randomized double-blind controlled trial with mirtazapine and paroxetine in patients with major depression (DSM-IV). Improvement was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score reduction of > or = 20%. Stable response was defined as > or = 50% HAM-D-17 score reduction at week 4 and week 6,…

AdultMalemedicine.medical_specialtyAdolescentMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatrySurvival analysisDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedPrognosisParoxetineSurvival AnalysisClinical trialPsychiatry and Mental healthParoxetineTreatment OutcomeAntidepressantDrug Therapy CombinationFemalePsychologySelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Handling forces for the use of different inhaler devices.

2019

Abstract Age and comorbidities can impact on the success of handling an inhaler. In this pilot study, we assessed finger strength in 62 participants (aged 5–17 years [n = 20], 18–65 years [n = 22] and > 65 years [n = 20]) by using different types of inhalers with integrated sensors (Respimat®, Breezhaler®, Aerolizer®, Genuair®, Diskus®, Ellipta®, HandiHaler®, Turbohaler® and a pressurized metered-dose inhaler [Atrovent®]). Parameters under investigation included the spontaneous and maximum achievable force and torque required to operate devices. Satisfaction with individual inhalers, and the relationship between satisfaction and strength, were also assessed. There was a marked difference in…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical SciencePilot Projects02 engineering and technology030226 pharmacology & pharmacyFingers03 medical and health sciencesYoung Adult0302 clinical medicineAge groupsRheumatic DiseasesAdministration InhalationMedicineHumansChildAgedAged 80 and overHand Strengthbusiness.industryInhalerNebulizers and VaporizersHealthy subjectsAge FactorsRheumatic diseaseEquipment DesignMiddle Aged021001 nanoscience & nanotechnologyPatient preferenceDry-powder inhalerPatient SatisfactionCase-Control StudiesChild PreschoolPhysical therapyFemale0210 nano-technologybusinessInternational journal of pharmaceutics
researchProduct

Mechanical work and efficiency in treadmill running at aerobic and anaerobic thresholds

1990

Mechanical work, mechanical power, energy consumption and mechanical efficiency were studied in constant-speed treadmill running of 5 min at seven different exercises around aerobic (AerT) and anaerobic (AnT) thresholds. The true efficiency of concentric (positive) mechanical work and gross efficiency of the whole body in seven male subjects were calculated. The total mechanical work was calculated from film through the translational, potential and rotational energy states as the sum of the changes of all the mechanical energy states in all body segments allowing energy transfer between segments and from energy state to state. The total energy consumption was measured by combining aerobic a…

AdultMalemedicine.medical_specialtyAdolescentPhysiologyPhysical ExertionDifferential ThresholdEfficiencyConcentricRunningAnimal sciencemedicineHumansAnaerobiosisTreadmillMechanical energyLegChemistryWork (physics)Energy consumptionAerobiosisBiomechanical PhenomenaRotational energyPhysical therapyRunning economyEnergy MetabolismAnaerobic exerciseActa Physiologica Scandinavica
researchProduct

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large mu…

2011

In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions. Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1). A multicenter randomized open-label trial was designed to assess the effectiveness of long-term alternating sequential L1-DFO versus L1 alone iron chelation therapy in β-TM patients. Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week was compared with L1 alone 75 mg/kg 7 days/week during 5-year follow-up. A total of 213 thalassemia patients were randomized and underwent intention-to-treat analysis. Statisticall…

AdultMalemedicine.medical_specialtyAdolescentPyridonesThalassemiaClinical BiochemistryDeferoxamineIron Chelating AgentsGastroenterologyDrug Administration Schedulelaw.inventionchemistry.chemical_compoundYoung AdultRandomized controlled triallawInternal medicineMedicineHumansDeferiproneAdverse effectGenetics (clinical)Survival analysisbusiness.industryBiochemistry (medical)Serum ferritin levelbeta-ThalassemiaHematologyIron chelation therapymedicine.diseaseChelation TherapyDeferoxamineTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessDeferiproneThalassemia Iron overload Iron chelation therapy Deferiprone (L1) Deferroxamine (DFO)medicine.drugFollow-Up StudiesHemoglobin
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Refinements in buccal mucosal graft urethroplasty for hypospadias repair

1998

We evaluated our experience with buccal mucosa in urethral reconstruction for complex hypospadias repair in a total of 62 children operated on at our institution since 1990 at a mean follow-up of 23 months. After the graft had been taken from the lower lip, with possible extension to the inner cheek, complete thinning of the graft was performed. The graft was then sutured in an onlay fashion to the urethral plate, and suprapubic urinary diversion was carried out for 3 weeks. The overall complication rate in this rather complex series of patients, including 26 "hypospadias cripples," was 13%; the complications involved 4 fistulas, 3 cases of graft necrosis, and only 1 meatal stenosis during …

AdultMalemedicine.medical_specialtyAdolescentUrologyUrethroplastymedicine.medical_treatmentUrethramedicineHypospadias repairHumansChildHypospadiasbusiness.industryGraft SurvivalUrinary diversionMouth MucosaSkin TransplantationBuccal administrationCheekmedicine.diseaseMeatal stenosisSurgeryPlastic surgeryTreatment Outcomemedicine.anatomical_structureEvaluation Studies as TopicHypospadiasChild PreschoolbusinessFollow-Up StudiesWorld Journal of Urology
researchProduct

Electromagnetically Generated Extracorporeal Shock Wave Lithotripsy and Adjuvant Combined Oral Litholysis for Therapy of Symptomatic Gallbladder Ston…

1991

A prospective study was conducted to evaluate effectivity, problems and adverse effects of extracorporeal shock wave lithotripsy (ESWL) using a newly developed electromagnetic biliary lithotriptor (Lithostar Plus, Siemens, Erlangen, FRG) for the treatment of selected patients presenting with symptomatic cholecystolithiasis. In addition to generally accepted criteria for the selection of patients, gallbladder contractility was established and pigment stones were excluded by computed tomography (CT). 80 out of 486 patients (63 females, 17 males, mean age 36, range 17-76 years) were selected for ESWL using a standardized diagnostic program. 62 out of 80 patients participating in the study had …

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdministration OralGallbladder StoneLithotripsyChenodeoxycholic AcidCholelithiasisLithotripsymedicineHumansProspective StudiesAgedUltrasonographybusiness.industryGallbladderUrsodeoxycholic AcidGastroenterologyMiddle AgedCombined Modality TherapyExtracorporeal shock wave lithotripsySurgerymedicine.anatomical_structureFemaleRadiologybusinessAdjuvantBiliary tract diseaseDigestion
researchProduct